Title: **Long-term effects of an unguided online cognitive behavioral therapy for chronic insulinia**

Short title: **Long-term effects of Internet CBTi**

Øystein Vedaa, PhD\(^1\,^2\,^3\); Susanne Hagatun, PhD \(^3\,^4\); Håvard Kallestad, PhD \(^1\,^2\); Ståle Pallesen, PhD \(^5\,^6\); Otto R. F. Smith, PhD \(^3\); Frances P. Thorndike, PhD \(^7\); Lee M. Ritterband, PhD \(^8\); Børge Sivertsen, PhD \(^1\,^3\,^9\)

\(^1\) Norwegian University of Science and Technology, Department of Mental Health, Faculty of Medicine and Health Sciences, Trondheim, Norway

\(^2\) St. Olavs University Hospital, Division of Mental Health Care, Department of Østmarka, Trondheim, Norway

\(^3\) Department of Health Promotion, Norwegian Institute of Public Health, Bergen, Norway

\(^4\) Department of Clinical Psychology, University of Bergen, Bergen, Norway

\(^5\) Department of Psychosocial Science, University of Bergen, Bergen, Norway

\(^6\) Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, Bergen, Norway

\(^7\) BeHealth Solutions, Charlottesville, Virginia, USA

\(^8\) Center for Behavioral Health and Technology, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System, Charlottesville, Virginia, USA
Corresponding author:

Øystein Vedaa, Ph.D.. Telephone: (00 47) 976 59 326, e-mail: Oystein.Vedaa@ntnu.no.

Department of Health Promotion, Norwegian Institute of Public Health, Zander Kaaes gate 7, 5018 Bergen, Norway

Institution where work was performed:

Department of Health Promotion, Norwegian Institute of Public Health, Zander Kaaes gate 7, 5018 Bergen, Norway

Authors contributions and approval:

All authors gave critical revision of the manuscript for important intellectual content and approved the manuscript before submission to JCSM.

Funding information:

The study was funded by the Norwegian Institute of Public Health and the Norwegian Research Council (project number 239985).

Disclosure statement:

This was not an industry supported study. F.P.T. and L.M.R. have equity ownership in BeHealth Solutions (Charlottesville, VA, USA), a company that develops and makes available products related to the research reported in this manuscript. BeHealth Solutions has licensed the SHUTi program and the software platform on which it was built from the University of Virginia. The terms of this arrangement have been reviewed and approved by
the University of Virginia in accordance with its conflict of interest policy. The other authors report that they have no conflicts of interest to disclose.

Clinical trial:

This study presents long-term follow-up data of a previous clinical trial. ClinicalTrials.gov Identifier: NCT02261272. Available at: https://clinicaltrials.gov/ct2/show/NCT02261272?cond=insomnia&cntry=NO&city=Bergen&rank=2

Number of tables: 2

Number of figures: 1

Abstract word count: 236

Brief summary word count: 95

Manuscript word count: 4832
ABSTRACT

Study Objectives: The aim of this study was to test the efficacy of a fully automated Internet-delivered CBTi (ICBTi) 18 months after the intervention period on sleep, daytime functioning, and beliefs about sleep for adults with chronic insomnia.

Methods: Participants in this study had participated in a RCT comparing the efficacy of unguided ICBTi with web-based patient education. Participants who had received ICBTi (N=95) completed online questionnaires and online sleep diaries 18 months after the intervention period. We used linear mixed models to study changes from baseline to post-assessment and to 18-month FU, and a separate mixed models analysis to study changes from post-assessment to 18-month FU.

Results: Mean age of the participants was 45.5 years (SD=12.6) and 64% were females. Sixty-six participants (70%) completed the 18-month follow-up (FU) assessment. There were significant improvements from baseline to 18-month FU on the Insomnia Severity Index (ISI) (Cohen d = 2.04 [95%CI, 1.66-2.42]) and the Bergen Insomnia Scale (BIS) (d = 1.64 [95%CI, 1.30-1.98]), levels of daytime fatigue (d = 0.85 [95%CI, 0.59-1.11]), psychological distress (d = 0.51 [95%CI, 0.29-0.73]), and beliefs about sleep (d = 1.44 [95%CI, 1.15-1.73]). Moderate to large effect size improvements were also shown on the diary-derived sleep variables. All improvements from baseline to post-assessment were essentially maintained to 18-month FU.

Conclusions: Unguided ICBTi appear to have sustained effects on sleep, daytime functioning, and beliefs about sleep up to 18-months after the intervention period.

Keywords: Insomnia, Internet, Cognitive behavioral therapy, Long-term, Daytime functioning
BRIEF SUMMARY

a) Internet-delivered Cognitive Behavioral Therapy for Insomnia (ICBTi) is efficacious as treatment for chronic insomnia. However, the long-term effectiveness of such treatment on sleep and daytime symptoms has received little attention in previous research.

b) We investigated whether improvements attained during ICBTi on sleep and daytime functioning were maintained 18 months after the intervention period.

c) ICBTi led to improved sleep and reduced symptoms of fatigue and psychological distress 18 months after the intervention period. These results add to the growing evidence verifying the efficacy of sustained improvements after self-guided Internet-delivered treatment for chronic insomnia.
INTRODUCTION

A recent meta-analysis established the efficacy of both guided and unguided ICBTi and reported significant and robust effects on insomnia severity and on several sleep diary outcomes. It was concluded that the effects, which in terms of effect sizes (Hedges’s g) ranged from 0.21 to 1.09, were comparable to those of in-person delivered CBTi. The meta-analysis further showed that the effects of ICBTi were maintained for insomnia severity and sleep quality at follow-up assessments (up to 48 weeks). However, for other sleep diary characteristics (i.e., sleep onset latency [SOL], wake after sleep onset [WASO], and total sleep time [TST]) maintenance of treatment effects was less consistently found. The authors recommended that future research should now focus on the long-term efficacy of ICBTi.

Three previous trials have examined the long-term outcomes of unguided ICBTi. Lancee et al. studied treatment gains of ICBTi 48 weeks after treatment completion, and found sustained effects. However, the design of that study intended to investigate whether the same self-help treatment given online or by paper-and-pencil material produced differential results. Due to this they needed to keep the two treatments as similar as possible resulting in significant restrictions to the extent interactive and personalized treatment elements were offered in the online treatment compared to other ICBTi-programs (e.g.). Ritterband et al. conducted a study comparing ICBTi to a control group and included a one-year follow-up assessment. Results demonstrated superior effects of ICBTi on insomnia severity and on sleep diary outcomes. That paper, however, did not report the effects of the treatment on other outcome measures than sleep, such as daytime fatigue and psychological wellbeing, which often are reported consequences of insomnia. Using the same ICBTi intervention as Ritterband et al. (i.e. SHUTi [Sleep Healthy Using the Internet™]), Batterham et al. investigated whether the efficacy of ICBT-I on depressive symptoms and insomnia severity were sustained over 18 months compared to a control group. They found symptoms of
depression, anxiety and insomnia decreased significantly after the intervention period and remained significantly lower compared to the control group for >18 months. Notably, the between group effect sizes on insomnia severity in that study reduced from 1.27 after the intervention period to 0.55 at 18 months follow up (FU) assessment. This may suggest an increase in sleep problems for the intervention group after the intervention period (or an improvement in the control group), but the power calculations are also likely influenced by the fact that only 19% of participants completed the 18-month assessment in that study. This level of attrition also makes the generality of the results on the long-term effects in that study somewhat uncertain.

In the present study, we report long-term results (18-months FU) from a randomized controlled trial comparing unguided ICBTi (SHUTi™) with web-based patient education. In previous publications we have demonstrated that the SHUTi-intervention was superior to the patient education (control condition) in terms of improving sleep, daytime functioning, and psychological wellbeing after the intervention period and that the treatment gains were relatively well maintained at 6-month follow-up. The aim of the present study is to examine whether the observed improvements in sleep and daytime functioning from baseline to after the intervention period are maintained at 18 months FU in the experimental group.

METHODS

Subjects and procedure

The participants in this study had participated in a randomized controlled trial comparing the effects of unguided ICBTi (n = 95) to web-based patient education (n = 86). Those who were randomized to receive unguided ICBTi, were invited to complete another set of online questionnaires and 10 days of sleep diaries 18 months following the intervention period (see consort diagram in Figure 1). Those who participated in the patient education control group
were given access to ICBTi after post-assessment, and thus could not be included in the 18-month FU study.

The inclusion procedure is detailed in a previous study and is therefore only briefly described here: Recruitment took place between November 2013 and March 2014. Eligible candidates were screened sequentially by a set of online screening questions, followed by a 15-minute telephone interview performed by a clinician. The online screening questionnaire was anonymous and noncommittal, where candidates received automated feedback based on their answers. Eligible candidates were encouraged to contact the research team through a dedicated e-mail if they wanted to be evaluated further for eligibility through a telephone interview. Candidates had to be 18 years or older, be fluent in Norwegian, have Internet access, and report sleep difficulties according to the DSM-IV-TR criteria for insomnia (difficulty initiating sleep, difficulty maintaining sleep, and/or early morning awakenings; in addition to daytime impairment due to sleep disturbance) 3 or more nights per week and for at least 3 months. Candidates were ineligible if they reported working night shifts, if they had another known sleep disorder such as obstructive sleep apnea, hypersomnia, narcolepsy, or were diagnosed with severe mental illness (e.g., current major depressive disorder, bipolar disorder, schizophrenic disorder). A single item question was used to assess sleep apnea in the online screening questionnaire: “During the last four weeks, how often have you experienced interrupted breathing during your sleep?” Those who answered “usually” or “always” were excluded from the study. Depression was assessed in the online screening questionnaire using MADRS-S, in which >19 points indicates moderate/severe depression and was set as exclusion criterion. Further assessment of the candidates’ sleep problems and mental health was done during the telephone interview; where those who reported being diagnosed with hypersomnia, narcolepsy, a major depressive disorder, bipolar disorder, or schizophrenic
disorder were excluded. Use of hypnotics for sleep problems or other medications was not an exclusion criterion.

**Treatment**

The ICBTi program (SHUTi™) consists of 6 online sessions designed to be completed weekly during a 9 week period. The weekly sessions covered the basic topics of CBTi, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. The treatment recommendations provided by the program are personalized for patients based on each individuals’ input in the program throughout the treatment (for more details about the SHUTi program, see Thorndike et al.). After the 9-week treatment period, participants were re-assessed with online questionnaires and online sleep diaries (10 diaries in a 14-day period). Participants were contacted at 6-month FU, and in terms of the current study, also at 18-month FU and asked to complete the same assessment (questionnaires and 10 days of sleep diaries).

**Ethics**

The study was approved by the Regional Committee for Medical and Health Research Ethics in SouthEast Norway (2012/1934 REK, SouthEast B). Informed consent was provided and participants were compensated NOK 500 (approximately USD 60) for completing the 18-month FU assessment. ClinicalTrials.gov Identifier: NCT02261272.

**Instruments**

*Insomnia Severity Index* (ISI) is a brief self-report instrument measuring the patient's perception of his or her insomnia. It contains seven questions that target the participants’ symptoms and consequences of insomnia, and the level of distress they experience in relation to these difficulties. Each item is rated on a 0–4 Likert scale, hence the composite scores
range from 0 to 28, where higher scores suggest more severe insomnia. The ISI is a reliable self-report measure and has demonstrated adequate sensitivity to changes in response to treatment, where participants are considered responders to treatment if the ISI score decreases by 8 or more points.\textsuperscript{14,15} An ISI score of less than 8 is the most widely used remission criterion.\textsuperscript{16} The instrument has previously demonstrated excellent internal consistency.\textsuperscript{15} Cronbach alphas at pre-, post-, and 18-month FU in the present study were .51, .73, and .87, respectively.

\textit{Bergen Insomnia Scale (BIS)}\textsuperscript{17} comprises six items that assesses symptoms of insomnia based on the American Psychiatric Association (APA)’s Diagnostic and Statistical Manual of Mental Disorders-IV-TR.\textsuperscript{18} Subjects are asked to indicate how many days a week (0-7) during the last month they have struggled with six specified symptoms of insomnia. The scale can be used as a continuous measure or as a dichotomous/diagnostic measure. Higher scores indicate more symptoms of insomnia when BIS is used as a continuous measure. The diagnostic criteria of insomnia are met with a score of $\geq 3$ on at least one of the first four items (night-time symptoms) and a score of $\geq 3$ on at least one of the last two items (daytime symptoms). Cronbach’s alpha of BIS was .58 at pre-treatment, .82 at post-treatment, and .85 at 18-month FU.

\textit{The Brief Dysfunctional Beliefs and Attitudes Scale (DBAS-16)}\textsuperscript{19} is a self-report questionnaire designed to identify various maladaptive sleep- and insomnia-related cognitions. Participants are given a list of 16 statements reflecting different beliefs and attitudes about sleep, and they are asked to indicate on a 10-point scale how much they agree with the statements. A high score indicates more maladaptive beliefs that are assumed to have a potential perpetuating effect on insomnia symptoms. The scale has proven adequate internal consistency both for clinical and research samples.\textsuperscript{19} Also, in the present study, internal
consistency was high, where Cronbach’s alphas for the DBAS-16 at the different assessment points were .81 at pre, .89 at post, and .89 at 18-month FU, respectively.

Sleep diaries\textsuperscript{20} that were completed online were used to register subjective sleep data, where participants provided daily estimates of their sleep the previous night during the baseline assessment, post-treatment assessment, and at 18-month FU (10 days of diaries in a 14-day window were required at each assessment point). Throughout the assessment periods, participants received automated daily reminders on e-mail to complete the sleep diary. The following measures were derived from the diary: Sleep onset latency (SOL), wake after sleep onset (WASO, time awake during the night), early morning awakening (EMA, time spent in bed after final wake-up), time in bed (TIB), total sleep time (TST), and sleep efficiency (SE, total sleep time as a percentage of time in bed). In the current study, the analyses were based on mean scores of the 10 days for each of the respective sleep diary parameters – in line with previous publications\textsuperscript{7,8}

\textit{The Hospital Anxiety and Depression Scale} (HADS) is a widely used measure of general psychological distress\textsuperscript{21}. The scale comprises 14 questions pertaining to non-vegetative symptoms of anxiety and depression. Each item is rated on a 0-4 Likert scale. A higher score indicates greater symptom severity. The HADS can be used to separately assess symptom severity of anxiety and depression. However, in the present study the subscales were combined into one general factor measuring psychological distress, adhering to previous studies that have demonstrated superior factor loadings on one general factor\textsuperscript{22,23}. Scores on the HADS using the general factor range between 0-56. The recommended cut-off point for identifying clinical cases of anxiety and depression is $\geq$8 on both subscales\textsuperscript{21,22}. Cronbach’s alphas at the different assessment points were .82 at pre, .83 at post, and .82 at 18-month FU.
Chalder Fatigue Questionnaire (CFQ)\textsuperscript{24} is a self-administered questionnaire used to measure the extent and severity of participants’ fatigue complaints. CFQ comprises 11 items addressing physical and psychological fatigue, and 2 items addressing the duration (from ‘less than one week’ through ‘six months or more’) and the frequency of fatigue complaints (i.e. how much of the time they feel fatigued; from ‘25\% of the time’ through ‘all the time’). Each item is answered on a 4-point scale ranging from asymptomatic to maximum symptomatology. A composite score including all 13 items was used in the present study with scores ranging from 0 to 39. Reliability measures of CFQ have been high both in clinical samples\textsuperscript{25} as well as in the general population.\textsuperscript{26} CFQ was chosen as a measure of fatigue in the present study since a Norwegian validated version was available.\textsuperscript{26} In the present study, Cronbach’s alphas for CFQ at the different assessment points were .84 at pre, .85 at post, and .86 at 18-month FU.

Statistics

All analyses were performed using IBM\textsuperscript{©} SPSS Statistics, version 23 (IBM SPSS Statistics, New York, USA). The long-term effects (18-month FU) of ICBTi were examined using linear mixed models for repeated-measures analysis, where all participants with baseline data were included in the analysis in line with the intention to treat principle. Two consecutive mixed model analyses were performed. In the first, baseline assessments were used as reference and compared to post-treatment and 18-month FU assessments; while in the second, post-treatment assessments were used as reference and compared to the 18-month FU assessments. Furthermore, we used independent samples t-tests and Chi-square test for independence to investigate differences between follow-up completers and those lost to follow-up.
No constraints were imposed on the covariance structure for repeated measures (type = unstructured). Mixed model analysis uses maximum likelihood estimation and can handle data that are missing at random (MAR) on dependent variables. Although there are no conclusive tests to prove the assumption of MAR, it is generally considered a more realistic assumption as compared to missing completely at random (MCAR). Under the assumption of MAR (missing at random), the estimates are still valid, and provide valuable information about the extent to which the changes from baseline to post-treatment are maintained at 18-month FU.

Effect sizes (Cohen’s d) were calculated in line with the recommendations of Carlson et al.\(^{27}\) and Morris\(^{28}\) and were based on the results from the mixed model analyses (estimated means and their standard errors). Effect size estimations were conducted in such a way that improvements always were reflected by positive effect sizes, whereas negative effect sizes consistently conveyed worsening. Effect sizes are shown in Table 1. Effect sizes are regarded as large (\(d = 0.8\)), moderate (\(d = 0.5\)), or small (\(d = 0.2\)) according to recognized guidelines.\(^{29}\)

**Sample size calculation**

Previous studies on face-to-face CBTi have yielded between-group effect sizes (Cohen’s \(d\)) commonly in the range from 0.5 to 1.0 on important sleep diary outcomes (SOL, WASO, number of awakenings, EMA, TIB, TST, and SE) at post assessment, while the first study that was carried out on the ICBTi SHUTi program compared to a wait-list control yielded between group effect-sizes in the range of 0.4 (total sleep time) to 1.0 (sleep onset latency) on sleep diary-derived variables at post. The present study was originally powered to be able to detect a difference between ICBTi and a patient education group at post treatment of 0.45 (for greater description, see first paper from this clinical trial\(^{7}\)). With a power of .80 at \(p=.05\) (two-tailed), the number of participants needed in each group in order to detect differences on the
sleep diary outcomes was estimated to be 79. The sample size was increased to account for an anticipated dropout rate of approximately 20%, and 205 participants with insomnia were finally included in the original study, where 95 of these were allocated to the ICBTi condition investigated in the present study. Furthermore, the present study has a repeated measures design using within-subject analyses only, which further strengthens the statistical power.

RESULTS

Sample characteristics

The sample characteristics have been described previously and are therefore only briefly described here. Mean age of the 95 participants was 45.5 years (SD=12.6) upon enrollment, and most were female (64%) and married/cohabiting (64%). Mean years of education was 16.3 (SD=3.2), which corresponds to a completed bachelor’s degree. Sixteen percent of the participants had been suffering from insomnia for 3-11 months, 58% for 1-10 years, and 26% for more than 10 years. Sixty-six (70%) of the 95 participants first enrolled in the study completed the 18-month FU assessment (Figure 1). No significant differences between 18-month FU completers and those lost to follow-up were observed on the parameters described above. However, those lost to 18-month FU had a somewhat higher baseline ISI score (M=18.6, SD=4.5) than the FU completers (M=16.9, SD=3.3), t (93) = 1.83, p=.041 (two tailed). There were no significant differences between FU completers and dropouts on any of the other variables.

The total number of individuals with clinical anxiety or depression identified with the HADS at baseline was 33 out of 95 (34.7%). Of these 33 participants, 78.8% completed the post-assessment and 72.7% completed the 18-month FU. Of the 62 participants who scored below the threshold for anxiety/depression at baseline, 82.3% completed the post-assessment and 67.7% completed the 18-month FU. Furthermore, we calculated the corresponding
assessment completion rates based on those who reported taking any form of medication for sleep problems (incl. z-hypnotics, antidepressants, antihistamines and melatonin) at baseline versus those who did not. In total, 23 of 95 participants (24.2%) used some form of sleep medication at baseline, of which 65.2% completed the post-assessment and 52.2% completed the 18-month FU. In comparison, of those who did not use any sleep medication at baseline, 86.1% completed the post-assessment and 75.0% completed the 18-month FU. However, as pointed out in the previous paragraph, non-completers of the 18-month FU were not more likely (although close to significant) to use sleep medication at baseline compared to those who did not use medication, $\chi^2(df = 1, n=95)=3.82, p=.051, \phi=-.23$.

**Baseline to post-treatment/18-month FU**

Table 1 presents a summary of the results from the linear mixed models. Results for the primary outcome measures of ISI and BIS showed large and significant improvements from baseline to post-treatment (ISI, $p<.001$; BIS, $p<.001$) and from baseline to 18-month FU assessment (ISI, $p<.001$; BIS, $p<.001$).

On secondary sleep outcomes, significant improvements were observed across all sleep diary parameters from baseline: SOL (to post-treatment, $p<.001$; to 18-month FU, $p<.001$), WASO (to post-treatment, $p<.001$; to 18-month FU, $p<.001$), and EMA (to post-treatment, $p<.001$; to 18-month FU, $p<.001$) with moderate to large effect sizes. Baseline SE of 72% ($SD=12.0$) improved to 87% ($SD=5.8$) at post-treatment ($p<.001$), and 84% ($SD=10.9$) at 18-month FU ($p<.001$) both with large effect sizes. Mean TST increased from 5.6 hours ($SD=1.4$) at baseline to 6.1 hours ($SD=0.9$) at post-treatment ($p<.001$), and 6.3 hours ($SD=1.0$) at 18-month FU ($p<.001$), both with small to moderate effect sizes.

Participants scored significantly lower on the DBAS-16 at post-treatment ($p<.001$) and at 18 month FU ($p<.001$) relative to baseline, both with large effect sizes. Psychological distress
(HADS) improved significantly from baseline to post-treatment \((p<.001)\) and to 18-month FU \((p<.001)\) with moderate effect sizes. The fatigue scores showed large effect size improvements from baseline to post-treatment \((p<.001)\) and to 18-month FU \((p<.001)\).

**Post-treatment to 18-month FU**

Overall, the improvements obtained at post-treatment were maintained at 18-month FU (Table 1). We found no significant changes on the ISI or the BIS from post-treatment to 18-month FU. Patient scores on DBAS-16 further improved from post-treatment to 18-month FU \((p=.030)\) with a small effect size. As for the sleep diary measures SOL \((p=.035)\), WASO \((p=.012)\), and EMA \((p=.010)\), small but significant setbacks were observed. Significant setbacks were also observed in terms of SE, where mean SE dropped from 87\% \((SD=8.4)\) at post-treatment to 84\% \((SD=10.7)\) at 18-month FU \((p=.002)\). TST significantly increased from post-treatment to 18-month FU \((p=.025)\), from 6.1 hours \((SD=0.9)\) to 6.3 hours \((SD=1.0)\), respectively. The improvements observed on the measure of psychological distress (HADS) after treatment completion remained stable at 18-month FU. In terms of fatigue (CFQ), a small setback was observed from post-treatment to 18-month FU \((p=.047)\).

**Insomnia remitters and responders**

Baseline data indicated a mean ISI score of 17.4 \((SD=3.7)\) (Table 2), which is within the range of moderate to severe clinical insomnia. At baseline, all participants reported an ISI score of 8 points or more, referring to the threshold for remission used in previous studies. At 18-month FU, 37\% reported an ISI score of less than 8 points, indicating that they were in remission. A decrease of \(\geq 8\) ISI points has been suggested as an indicator of a responder to the treatment, and, at 18-month FU, 46\% fulfilled this criterion. All participants meet the BIS criteria for insomnia at baseline, whereas 53\% were in remission at 18-month FU.

**DISCUSSION**
The purpose of the present study was to investigate the extent to which the observed improvements from baseline to after the intervention period are also maintained at 18 months after the intervention period. The study sample comprised the experimental group of a previously published RCT comparing ICBTi to web-based patient education, where superiority of ICBTi over patient education was demonstrated short-term.\textsuperscript{7,8} Findings in the present study indicate that the effects for the ICBTi group overall were good at 18-month FU evaluation, reflected by effect sizes ranging from 0.5 (SOL) to 2.0 (ISI) on all outcome measures. Compared to studies with shorter FU time, the overall effects in the present study appeared slightly higher than those reported in recent meta-analyses on self-help interventions for insomnia,\textsuperscript{1,31} and are comparable in magnitude to those found in similar studies on fully automated ICBTi\textsuperscript{3,4,32} and in-person delivered CBTi.\textsuperscript{33}

It is particularly important to establish the long-term effects of unguided self-help interventions because of the potential for cost-effective dissemination on a population level. Current evidence suggests that interventions including elements of therapist support are somewhat more effective than those without.\textsuperscript{1} However, we found that large and sustained effects also could be achieved using fully automated ICBTi. This is especially notable as only those with severe psychiatric comorbidity were excluded, whereas disorders like mild to moderate depression and anxiety disorders were included. The present report adds to the list of studies showing promising effects of treatments that can replicate effects of in-person CBTi, both in terms of individualizing treatment and making the therapeutic concepts accessible for participants through interactive educational tools.\textsuperscript{3,4,32,34,35}

On most parameters, participants showed the greatest improvement immediately after completing the treatment. If small setbacks occurred, they were observed at 18-month FU. Still, the setbacks from post-treatment to 18-month FU on sleep diary measures appeared negligible considering that mean SOL, WASO, and EMA still remained below the clinically
meaningful threshold of 30 minutes at 18-month FU,\textsuperscript{36} and SE decreased from 87% after the intervention period to 84% at 18-month FU, which is only marginally below the clinical threshold of 85%.\textsuperscript{37} Importantly, a significant improvement on total sleep time (TST) from treatment completion to 18-month FU was observed. The sleep diary data results are interesting as the recent meta-analysis by Zachariae et al.\textsuperscript{1} render the long-term effects of ICBTi on sleep diary outcomes somewhat elusive, particularly after adjusting for possible publication bias.

Increase in TST from treatment termination to follow-up is a phenomenon also shown in studies on in-person delivered CBTi; where TST typically remain unchanged or even reduced during the initial intervention, but increases at FU evaluation.\textsuperscript{37-39} Many participants may at post-treatment still be adhering to a limited time in bed (cf. sleep restriction), and spend the following weeks or months reaching a sleep duration that meets their needs. A transient feature of sleep restriction is consequently an elevated sleep drive that may give rise to an artificially high SE (and correspondingly low SOL, WASO and EMA), which might be expected to ebb somewhat and then to stabilize as TST increases to match the participants sleep need. However, the finding that fewer participants were in remission at FU compared to post-treatment as defined by the ISI or BIS suggests that a few participants experienced relapse of sleep problems (Table 2). In addition, we found a small increase in fatigue scores from treatment completion to 18-month FU. These findings are in contrast to those reported from a three-year follow-up study comparing guided with unguided ICBTi, reporting that more participants in both conditions were in remission at FU as compared to post-treatment.\textsuperscript{40} Similarly, the recent study by Ritterband et al.\textsuperscript{4} assessing the effects of a fully automated ICBTi also indicated that more people were in remission at 1-year FU, as compared to 6-month FU and post-treatment.
Even though there was a small but significant setback after the intervention period (post-treatment to 18-month FU) in levels of fatigue, the effect size improvements from baseline to 18-month FU evaluation remained large. Thus, we overall conclude that the beneficial effects of the treatment on fatigue complaints were substantial and lasting. These findings are in line with previous studies demonstrating short-term effects, but the current study extends these results to evidence of sustained effects beyond treatment completion. Furthermore, on general psychological distress, we demonstrated moderate effect size improvements from baseline to post-assessment and to 18-month FU, and there was no significant change between post-assessment and FU evaluation. This is in line with prior results that show treatment targeting insomnia reduces psychological symptoms, both when the treatment is delivered in person and when delivered online. One study found that unguided ICBTi compared to a control group reduced symptoms of anxiety and depression with moderate between group effect sizes, where the effects were maintained and appeared unabated to a 18-month FU evaluation. The fact that only 19% of participants completed the 18-month assessment in that study makes the results on the long-term effects somewhat uncertain. However, 70% of the participants in the present study completed the 18-month FU, and our observations confirm that the effects appear maintained up to 18-months after the intervention period. A cautionary note when interpreting these results is that only 34% of the participants were in the clinical range of anxiety/depression at baseline. These effects are nevertheless noteworthy considering that the ICBTi treatment does not directly address anxiety and depressive symptoms and the intervention does not propound any booster sessions. These findings suggest that the presence of symptoms of mild to moderate psychological distress and fatigue should not be a pretext to postpone insomnia treatment, which delivered online might be a valuable supplement to treatment of comorbid conditions.

Limitations
It should be noted that the 18-month FU evaluation in the current study did not include a control group, which precludes firm causal inferences about the long-term effects of ICBTi due to lack of control for several threats to internal validity. Participants typically experience a peak in symptoms upon seeking treatment, where it is reasonable to expect a regression towards mean with passage of time. However, chronic insomnia emerges as a persistent disorder where nearly 70% will still have the disorder a year later, and 50% three years later when left untreated. Still, we know little about the prognosis of untreated insomnia. Participants in the present study had long histories of chronic insomnia, which makes spontaneous recovery of the magnitude we observed an unlikely explanation. Participants with a higher ISI score at baseline were more likely not to complete the 18 month FU, and those who used sleep medication at baseline had a tendency (close to significant) towards not completing the 18 month FU, which potentially can lead to a bias in the present study. It is possible that missing data at FU is partly MNAR. This can imply a risk of under- or overestimation of the true change. A sensitivity analysis is recommended in order to check how MNAR may impact change estimates. This was nevertheless not carried out due to the relatively low N in the current sample. One limitation of the present study is that other sleep disorders were only assessed through a short online screening questionnaire and a telephone interview, and no objective measures or standardized assessments were used to rule out other sleep disorders. It is also a limitation that no objective sleep measure (e.g. actigraphy or polysomnography) was used as outcome measure. Another limitation pertains to the low internal consistency of the baseline scores of the ISI and the BIS; however, this is most likely a reflection of the restricted range of scores at this measurement time. It should also be noted that the measure of fatigue used in this study (the CFQ) is not among the consensus recommendations for assessments in insomnia. CFQ has nevertheless shown good psychometric properties with high reliability also in clinical samples. Most participants were
recruited after various media appearances of the authors and may thus represent a self-selected group of resourceful and especially motivated individuals. In line with this, the average education level in the current sample was high; 76.2% had completed at least one year of higher education (university/university college level), compared to 32.2% in the Norwegian population as a whole (Statistics Norway). As such, we cannot know whether the observed effects in the present study are transferable to participants referred from general practice. However, this is a limitation that pertains to most studies on fully automated ICBTi (e.g.\textsuperscript{3,4,32,34}).

Conclusion

Overall, our results add to the small, but growing evidence that the effects of unguided ICBTi are of a substantial magnitude, comparable to in-person CBTi and well maintained long-term.\textsuperscript{2,40} The overall effects seem largest immediately after the intervention period and appear to become somewhat reduced at FU evaluations. It should be noted that booster sessions were not offered in the present study, and we might have seen even better results at 18-month FU if this had been offered. Further work on the long-term effects of ICBTi should evaluate the effects of treatment in study designs that also include control groups. Also, future studies should incorporate a wider range of long-term functional outcome measures that go beyond sleep and symptoms of distress, such as sick leave, medication use, use of health care services, and other measures of general health. Studies should also aim to evaluate the effectiveness of ICBTi in clinical settings, both in comparison to in-person delivered CBTi and in the context of stepped-care models.\textsuperscript{46}
List of abbreviations

BIS – Bergen Insomnia Scale

CBTi – Cognitive Behavioral Therapy for Insomnia

CFQ - Chalder Fatigue Questionnaire

DBAS – Dysfunctional Beliefs and Attitudes Scale


EMA – Early Morning Awakening

FU – Follow Up

HADS - Hospital Anxiety and Depression Scale

ICBTi – Internet-delivered Cognitive Behavioral Therapy for Insomnia

ISI – Insomnia Severity Index

MAR – Missing at Random

MCAR – Missing Completely at Random

REK – Regional Ethics Committee

SE – Sleep Efficiency

SHUTi – Sleep Healthy Using the Internet

SOL – Sleep Onset Latency

TIB – Time In Bed

TST – Total Sleep Time

WASO – Wake After Sleep Onset
REFERENCES


23. Kjærgaard M, Arfwedson Wang CE, Waterloo K, Jorde R. A study of the psychometric properties of the Beck Depression Inventory II, the Montgomery and Åsberg Depression


Figure 1. Consort diagram and participant flow (note that only the results from 18-month assessment are reported in this study).
### Table 2. Insomnia remitters and responders (N=95).

<table>
<thead>
<tr>
<th></th>
<th>Baseline (n=95)</th>
<th>Post-treatment (n=77)</th>
<th>18-month FU (n=67)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ISI mean (SD)</strong></td>
<td>17.4 (3.7)</td>
<td>8.8 (5.8)</td>
<td>9.8 (7.3)</td>
</tr>
<tr>
<td><strong>ISI remitters (cut off &lt;8)</strong></td>
<td>NA</td>
<td>48%</td>
<td>37%</td>
</tr>
<tr>
<td><strong>ISI responders (reduction of ≥8)</strong></td>
<td>56%</td>
<td></td>
<td>46%</td>
</tr>
<tr>
<td><strong>BIS mean (SD)</strong></td>
<td>25.9 (7.1)</td>
<td>12.5 (8.3)</td>
<td>13.6 (9.8)</td>
</tr>
<tr>
<td><strong>BIS remitters</strong></td>
<td>NA</td>
<td>51%</td>
<td>53%</td>
</tr>
</tbody>
</table>

*Note.* ISI = Insomnia severity index; BIS = Bergen insomnia scale. ISI remitters are participants who attain an ISI score of less than 8 points at the different assessments. ISI responders are participants who achieve a reduction of ≥8 ISI points relative to baseline assessment. BIS remitters are participants who either scored less than 3 on all of the first four items and/or scored less than 3 on the last two items.
Table 1. Results from linear mixed models ($N = 95$).

<table>
<thead>
<tr>
<th>Sleep variables</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SE</td>
<td>95% CI (mean)</td>
<td>$d$ (baseline to post/18mFU)</td>
<td>95% CI (baseline to post/18mFU)</td>
<td>$d$ (post to 18mFU)</td>
</tr>
<tr>
<td><strong>Insomnia Severity Index (ISI)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>17.4</td>
<td>0.4</td>
<td>16.6 to 18.2</td>
<td>2.30***</td>
<td>1.90 to 2.70</td>
<td>-0.17</td>
</tr>
<tr>
<td>Post treatment</td>
<td>8.8</td>
<td>0.6</td>
<td>7.6 to 10.0</td>
<td>2.04***</td>
<td>1.66 to 2.42</td>
<td>-0.17</td>
</tr>
<tr>
<td>18-month FU</td>
<td>9.8</td>
<td>0.7</td>
<td>8.3 to 11.3</td>
<td>2.04***</td>
<td>1.66 to 2.42</td>
<td>-0.17</td>
</tr>
<tr>
<td><strong>Bergen Insomnia Scale (BIS)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>25.9</td>
<td>0.7</td>
<td>24.4 to 27.3</td>
<td>1.53***</td>
<td>1.24 to 1.82</td>
<td>0.09</td>
</tr>
<tr>
<td>Post treatment</td>
<td>15.0</td>
<td>0.9</td>
<td>13.2 to 16.7</td>
<td>1.53***</td>
<td>1.24 to 1.82</td>
<td>0.09</td>
</tr>
<tr>
<td>18-month FU</td>
<td>14.2</td>
<td>1.2</td>
<td>11.8 to 16.6</td>
<td>1.64***</td>
<td>1.30 to 1.98</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>DBAS-16</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>5.0</td>
<td>0.2</td>
<td>4.7 to 5.3</td>
<td>0.87***</td>
<td>0.65 to 1.09</td>
<td>0.21*</td>
</tr>
<tr>
<td>Post treatment</td>
<td>3.3</td>
<td>0.2</td>
<td>2.9 to 3.7</td>
<td>0.87***</td>
<td>0.65 to 1.09</td>
<td>0.21*</td>
</tr>
<tr>
<td>18-month FU</td>
<td>2.9</td>
<td>0.2</td>
<td>2.5 to 3.3</td>
<td>1.08***</td>
<td>0.83 to 1.13</td>
<td>0.21*</td>
</tr>
<tr>
<td><strong>Sleep onset latency (min)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>48.5</td>
<td>4.3</td>
<td>40.0 to 57.0</td>
<td>0.65***</td>
<td>0.45 to 0.85</td>
<td>-0.31*</td>
</tr>
<tr>
<td>Post treatment</td>
<td>21.1</td>
<td>1.9</td>
<td>17.4 to 24.8</td>
<td>0.65***</td>
<td>0.45 to 0.85</td>
<td>-0.31*</td>
</tr>
<tr>
<td>18-month FU</td>
<td>26.8</td>
<td>3.0</td>
<td>20.8 to 32.9</td>
<td>0.52***</td>
<td>0.33 to 0.71</td>
<td>-0.31*</td>
</tr>
<tr>
<td><strong>Wake after sleep onset (min)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>44.6</td>
<td>3.3</td>
<td>38.1 to 51.2</td>
<td>0.81***</td>
<td>0.58 to 1.04</td>
<td>-0.36**</td>
</tr>
<tr>
<td>Post treatment</td>
<td>18.8</td>
<td>2.1</td>
<td>14.5 to 23.0</td>
<td>0.81***</td>
<td>0.58 to 1.04</td>
<td>-0.36**</td>
</tr>
<tr>
<td>18-month FU</td>
<td>26.3</td>
<td>2.8</td>
<td>20.7 to 31.9</td>
<td>0.57***</td>
<td>0.32 to 0.82</td>
<td>-0.36**</td>
</tr>
<tr>
<td><strong>Early morning awakening (min)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>38.4</td>
<td>2.8</td>
<td>32.9 to 43.9</td>
<td>0.84***</td>
<td>0.60 to 1.08</td>
<td>-0.24*</td>
</tr>
<tr>
<td>Post treatment</td>
<td>15.9</td>
<td>1.9</td>
<td>12.2 to 19.6</td>
<td>0.84***</td>
<td>0.60 to 1.08</td>
<td>-0.24*</td>
</tr>
<tr>
<td>18-month FU</td>
<td>20.2</td>
<td>2.1</td>
<td>16.0 to 24.5</td>
<td>0.67***</td>
<td>0.45 to 0.89</td>
<td>-0.24*</td>
</tr>
<tr>
<td><strong>Time in bed (hours)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:**
- $d$ values indicate the magnitude of change.
- $***$, ***, *$ indicate statistical significance at the 0.001, 0.01, and 0.05 levels, respectively.
<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Post treatment</th>
<th>18-month FU</th>
<th>Effect Size</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total sleep time (hours)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>7.8</td>
<td>7.0</td>
<td>7.5</td>
<td>-0.79***</td>
<td>-1.00 to -0.58</td>
</tr>
<tr>
<td>Post treatment</td>
<td></td>
<td>6.1</td>
<td>6.3</td>
<td>0.44***</td>
<td>0.29 to 0.59</td>
</tr>
<tr>
<td>18-month FU</td>
<td></td>
<td>6.3</td>
<td>6.5</td>
<td>0.62***</td>
<td>0.41 to 0.83</td>
</tr>
<tr>
<td><strong>Sleep efficiency (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>72.1</td>
<td>86.8</td>
<td>84.1</td>
<td>1.23***</td>
<td>0.97 to 1.49</td>
</tr>
<tr>
<td>Post treatment</td>
<td></td>
<td>85.1</td>
<td>81.8</td>
<td>1.00***</td>
<td>0.75 to 1.25</td>
</tr>
<tr>
<td>18-month FU</td>
<td></td>
<td>85.1</td>
<td>86.3</td>
<td>0.85***</td>
<td>0.59 to 1.11</td>
</tr>
<tr>
<td><strong>Daytime functioning</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HADS total score</td>
<td>9.7</td>
<td>6.8</td>
<td>6.9</td>
<td>0.54***</td>
<td>0.37 to 0.71</td>
</tr>
<tr>
<td>Post treatment</td>
<td></td>
<td>5.7</td>
<td>5.7</td>
<td>0.51***</td>
<td>0.29 to 0.73</td>
</tr>
<tr>
<td>18-month FU</td>
<td></td>
<td>5.7</td>
<td>8.1</td>
<td></td>
<td>-0.03 to -0.18</td>
</tr>
<tr>
<td>Chalder Fatigue Questionnaire</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>18.9</td>
<td>12.9</td>
<td>14.4</td>
<td>1.12***</td>
<td>0.85 to 1.39</td>
</tr>
<tr>
<td>Post treatment</td>
<td></td>
<td>11.7</td>
<td>13.0</td>
<td>0.85***</td>
<td>0.59 to 1.11</td>
</tr>
<tr>
<td>18-month FU</td>
<td></td>
<td>14.4</td>
<td>15.7</td>
<td>-0.25*</td>
<td>-0.47 to -0.03</td>
</tr>
</tbody>
</table>

*Note. Effect sizes are specified relative to baseline and to post treatment. Effect size estimations were conducted in such a way that improvements always were reflected by positive effect sizes, whereas negative effect sizes consistently conveyed worsening. * p<.05; ** p<.01; *** p<.001